Body and heart weight, Phe and KCl contraction, and ACh and SNP relaxation in aortic rings of control and LD or HD L-NAME + AngII ± EPL–treated WT and cav-1−/− mice
Data represent mean ± S.E.M.; n = 4–13
| WT | cav-1−/− | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Control | L-NAME + AngII LD | L-NAME + AngII HD | L-NAME + AngII LD + EPL | L-NAME + AngII HD + EPL | Control | L-NAME + AngII LD | L-NAME + AngII HD | L-NAME + AngII LD + EPL | L-NAME + AngII HD + EPL | |
| Body weight (g) | 25.9 ± 0.9 | 26.3 ± 1.4 | 28.4 ± 1.1 | 25.6 ± 1.8 | 26.7 ± 2.0 | 23.5 ± 0.09 | 22.3 ± 0.9# | 21.8 ± 0.7# | 21.2 ± 0.2# | 22.8 ± 1.3 |
| Heart weight (mg) | 154.4 ± 8.3 | 175.5 ± 28.4 | 182.4 ± 5.6* | 158.5 ± 17.0 | 186.0 ± 15.2 | 150.6 ± 7.2 | 158.8 ± 11.6 | 169.0 ± 9.0 | 168.3 ± 19.2 | 198.9 ± 18.8 |
| Heart/body (mg/g) | 6.0 ± 0.2 | 6.6 ± 0.9 | 6.5 ± 0.2 | 6.1 ± 0.3 | 7.4 ± 1.1 | 6.5 ± 0.3 | 7.1 ± 0.5 | 7.9 ± 0.4*,# | 7.9 ± 0.9* | 8.9 ± 0.9 |
| Phe maximum (10−5 M) | ||||||||||
| Contraction (g) | 0.42 ± 0.09 | 0.50 ± 0.10 | 0.37 ± 0.08 | 0.90 ± 0.28* | 0.88 ± 0.12*,§ | 0.35 ± 0.12 | 0.50 ± 0.18 | 0.28 ± 0.06 | 0.37 ± 0.15 | 0.35 ± 0.07# |
| +L-NAME (3 × 10−4 M) | 0.94 ± 0.20† | 0.74 ± 0.24 | 0.36 ± 0.06 | 1.07 ± 0.13 | 1.10 ± 0.34 | 0.78 ± 0.18 | 1.27 ± 0.08† | 0.65 ± 0.10† | 0.68 ± 0.30 | 0.41 ± 0.14 |
| +ODQ (10−5 M) | 0.79 ± 0.25 | 0.75 ± 0.15 | 0.42 ± 0.03 | 1.39 ± 0.42 | 0.86 ± 0.30 | 0.63 ± 0.30 | 0.97 ± 0.17 | 0.40 ± 0.05 | 0.48 ± 0.32 | 0.71 ± 0.13† |
| −Endo | 0.73 ± 0.07 | 0.50 ± 0.34 | N.D. | 0.89 ± 0.21 | N.D. | 0.45 ± 0.14 | 0.88 ± 0.13 | N.D. | 0.52 ± 0.14 | N.D. |
| Phe pED50 (−log M) | 7.19 ± 0.13 | 7.37 ± 0.23 | 7.09 ± 0.21 | 7.75 ± 0.85 | 6.85 ± 0.12 | 6.91 ± 0.12 | 7.26 ± 0.23 | 6.90 ± 0.10 | 7.12 ± 0.32 | 6.88 ± 0.15 |
| +L-NAME | 7.37 ± 0.12 | 6.96 ± 0.29 | 7.22 ± 0.77 | 7.28 ± 0.50 | 6.47 ± 0.44 | 6.72 ± 0.20# | 8.12 ± 0.36* | 6.08 ± 0.43# | 6.26 ± 0.38 | 6.43 ± 0.22 |
| +ODQ | 7.27 ± 0.17 | 7.07 ± 0.32 | 6.05 ± 0.01*,† | 7.63 ± 1.08 | 6.38 ± 0.69 | 6.62 ± 0.24 | 7.04 ± 0.64 | 6.26 ± 0.38 | 8.22 ± 0.52* | 6.45 ± 0.31 |
| −Endo | 7.13 ± 0.10 | 7.64 ± 0.40 | N.D. | 7.93 ± 1.18 | N.D. | 6.92 ± 0.07 | 7.71 ± 0.79 | N.D. | 7.02 ± 0.34 | N.D. |
| KCl contraction (g) | 0.30 ± 0.06 | 0.39 ± 0.08 | 0.33 ± 0.07 | 0.66 ± 0.19 | 0.63 ± 0.10* | 0.28 ± 0.10 | 0.45 ± 0.17 | 0.33 ± 0.07 | 0.32 ± 0.13 | 0.40 ± 0.04 |
| Phe maximum contraction | ||||||||||
| (% 96 mM KCl) | 137.1 ± 11.4 | 129.4 ± 11.1 | 117.4 ± 10.2 | 153.3 ± 20.3 | 141.8 ± 8.9 | 125.6 ± 10.9 | 132.2 ± 15.2 | 101.9 ± 20.2 | 124.7 ± 19.8 | 90.1 ± 10.5*,# |
| +L-NAME | 196.8 ± 22.4† | 141.7 ± 17.3 | 121.4 ± 30.2 | 160.1 ± 2.5 | 124.7 ± 3.2 | 179.4 ± 42.4 | 176.7 ± 6.7 | 180.5 ± 11.3 | 130.3 ± 16.0 | 98.2 ± 25.6 |
| +ODQ | 186.3 ± 17.1† | 164.0 ± 13.0 | 108.4 ± 19.3* | 139.2 ± 46.7 | 133.9 ± 2.5 | 115.1 ± 27.5 | 94.1 ± 9.5# | 176.6 ± 9.9 | 145.0 ± 42.0 | 124.5 ± 24.3 |
| −Endo | 115.4 ± 7.6 | 100.0 ± 16.7 | N.D. | 150.4 ± 33.2 | N.D. | 158.2 ± 10.1# | 225.6 ± 66.5 | N.D. | 202.8 ± 44.0 | N.D. |
| ACh (10−5 M) % relaxation | 22.3 ± 4.3 | 19.6 ± 3.8 | 51.8 ± 9.6* | 26.2 ± 10.8 | 35.6 ± 13.1 | 68.3 ± 6.9 | 70.7 ± 9.1 | 77.1 ± 7.2 | 69.4 ± 10.6 | 72.7 ± 10.9 |
| pED50 (−log M) | 7.00 ± 0.35 | 6.50 ± 0.21 | 7.53 ± 0.35 | 6.29 ± 0.35 | 6.96 ± 0.13 | 6.95 ± 0.18 | 6.60 ± 0.20 | 6.88 ± 0.23 | 6.66 ± 0.29 | 6.97 ± 0.27 |
| SNP (10−8 M) % relaxation | 45.6 ± 7.1 | 47.5 ± 5.9 | 78.1 ± 11.4* | 73.3 ± 13.1 | 67.6 ± 18.3 | 72.61 ± 7.91 | 67.2 ± 6.8 | 66.5 ± 16.4 | 85.4 ± 9.1 | 51.8 ± 21.5 |
| pED50 (−log M) | 7.94 ± 0.13 | 7.88 ± 0.23 | 8.63 ± 0.38 | 8.38 ± 0.14 | 8.41 ± 0.38 | 8.32 ± 0.20 | 8.38 ± 0.14 | 8.26 ± 0.26 | 8.74 ± 0.15 | 8.11 ± 0.40 |
N.D., not determined because of insufficient mouse tissue.
↵* Significantly different (P < 0.05) from respective control WT or cav-1−/− mice; §P < 0.05, EPL-treated versus without EPL treatment; #P < 0.05, cav-1−/− versus WT; †P < 0.05, L-NAME or ODQ-treated or endothelium-denuded arteries versus control nontreated arteries.